The Centers for Disease Control and Prevention (CDC) updated its RSV vaccine guidance for seniors for this upcoming respiratory viral season, saying the new recommendations are meant to simplify decision-making for patients and clinicians. The new guidan
"We were able to use the power of big data to determine RSV vaccine effectiveness, information [that is] needed to inform vaccine policy,” Grannis said. Of course, “no vaccine is 100 percent effective," said study co-author Brian Dixon. But, "an 80 percent vaccine effectiveness rate is...
Program Guide Sitemap About Us Advertise CBS Television Jobs Public File for WBZ-TV Public File for WSBK-TV / myTV38 Public Inspection File Help FCC Applications EEO ReportBe the first to know Get browser notifications for breaking news, live events, and exclusive reporting. Not Now Turn On...
Vaccine makers are still studying when seniors might need to come back for a booster dose of RSV vaccine in the coming years. They also have yet to decide on a final price, further complicating broader recommendations. GSK said their vaccine could be priced between $200 and $295 per dose, ...
Investors have high hopes for the long-term potential of Moderna's mRNA product pipeline: Shares of the company are up more than 40% this year after falling nearly 45% in 2023. Vaccine trial data The FDA was initially slated to make a decision on Moderna'...
The company’s respiratory syncytial virus vaccine Arexvy can elicit similar levels of immune protection in adults aged 50 to 59 as in its approved population, finds results from a late-stage study.